CTI BioPharma Balance Sheet - Quarterly (NASDAQ:CTIC)

Add to My Stocks
$1.88 $0.02 (1.08%) CTIC stock closing price Sep 18, 2018 (Closing)

A thorough fundamental analysis involves using data from CTI BioPharma balance sheet, apart from other financial statements, to value the business. How cash on hand has increased or decreased is one of the many indicators used while undertaking the CTI BioPharma stock analysis, and provides insights into the firm's financial performance. Quarterly results announcements include the release of all three financial statements, of which the balance sheet is one. The balance sheet shows total liabilities of $38.94M and shareholders equity of $63.65M. CTI BioPharma revenue and CTI BioPharma operating cash flow are important in understanding the financial capacity of the company.

View and download CTI BioPharma quarterly results to get the balance sheet details for the latest 40 quarters data.
show more
View Previous Quarters
View Next Quarters
Fiscal year is Jan - Dec2018 Q22018 Q12017 Q42017 Q32017 Q22017 Q12016 Q42016 Q32016 Q22016 Q1
Marketable Securities27.45M---------
Raw Materials----------
Work In Progress1.07M1.13M1.52M---2.55M2.94M3.17M3.29M
Finished Goods----------
Notes Receivable----------
Other Current Assets1.54M1.78M1.87M1.42M1.37M1.55M2.14M1.77M2.43M5.72M
Total Current Assets
Property Plant & Equipment--9.92M---11.82M---
Accumulated Depreciation--7.56M---8.8M---
Net Property Plant & Equipment
Investment & Advances----------
Other Non-Current Assets----------
Deferred Charges----------
Deposits & Other Assets5.45M5.73M5.59M5.49M5.32M5.06M4.99M5.35M5.31M5.88M
Total Assets
Notes Payable----------
Accounts Payable3.72M2.19M2.58M2.02M4.01M11.87M7.22M13.66M14.03M17.71M
Current Portion Long-Term Debt2.59M1.25M-7.76M8.41M8.17M7.94M7.71M7.49M7.28M
Current Portion Capital Leases----------
Accrued Expenses14.24M14.77M13.89M14.97M22.07M20.9M24.76M22.83M16.98M18.95M
Income Taxes Payable----------
Other Current Liabilities1.69M2.01M2.33M1.44M1.95M--2.08M2.23M2.4M
Total Current Liabilities
Deferred Taxes/Income----------
Convertible Debt----------
Long-Term Debt11.67M12.88M13.57M7.02M7M9.19M11.31M13.37M15.37M17.31M
Non-Current Capital Leases----------
Other Long-Term Liabilities5.03M5.25M5.46M3.17M3.33M3.47M3.61M3.75M3.96M4.09M
Total Liabilities
Minority Interest----------
Preferred Stock--1.09M1.09M1.09M-----
Common Stock Net--2.22B2.22B2.22B2.17B2.17B2.17B2.16B2.16B
Capital Surplus2.29B2.29B--------
Retained Earnings-2.21B-2.2B-2.2B-2.18B-2.17B-2.17B-2.15B-2.14B-2.11B-2.1B
Treasury Stock----------
Other Liabilities-15.64M-12.54M-11.99M-12.04M-12.13M-12.28M-12.21M-11.76M-11.64M-11.26M
Shareholders Equity63.65M77.04M16.09M28.41M38.92M-10.37M7.75M12.51M36.75M54.74M
Total Liabilities & Shareholders Equity102.59M115.72M54.88M65.53M86.33M44.66M63.84M76.48M97.63M123.44M
All figures in USD. M: Millions of USD, B: Billions of USD.
View Previous Quarters
View Next Quarters

Most investors just check the CTI BioPharma stock price, and CTI BioPharma historical stock prices before investing. While share price is an important factor, one should also look at financials and valuation metrics like the CTI BioPharma PE ratio chart. Below is a brief explanation of common balance sheet terms:

  • Assets: An asset is a resource that a corporation like CTI BioPharma owns and has economic value. The two major types of assets are: fixed assets like real estate, plant and machinery and current assets like cash, marketable securities and inventory. The total asset value for CTIC stock as of 2018 Q2 is $102.59M. Its easy to associate the term with manufacturing companies, which invest a lot in factories and equipment. However, the same cannot be said about tech stocks.
  • Liabilities: The total liabilities of CTI BioPharma for the quarter 2018 Q2 total to $38.94M. Liabilities for a company like CTI BioPharma include bank loans, services which have been availed for which a settlement in the form of cash/ asset transfer needs to be done in future etc. A firm takes on such obligations to grow its business which in turn will generate future economic benefits for its business.

CTI BioPharma Balance Sheet - Key Ratios

Current ratio
Debt to equity ratio
Asset turnover ratio
Receivables turnover
Price to book ratio